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Sir
We read with great interest the article by Al-Mufti et al (1999) 
(Br J Cancer 79: 1665–1671). However, we found the concept on
which their study design was based needs to be clarified. The cyto-
toxic action of a chemotherapeutic drug on cancer cells is different
from that of a therapeutic radiopharmaceutical. For a chemothera-
peutic drug such as a methylating agent to produce its cytotoxicity,
its molecules need to enter the cancer cells before it can act on
their DNA. That is why P-glycoprotein, which causes efflux of the
drug molecule out of the cells, leads to drug resistance. On the
other hand, the radiation-emiting isotope contained in a radiophar-
maceutical produces its cytotoxic effect by bombarding the DNA
of the cancer cells with beta particles or depositing radiation
energy to the cells in some other manner. This can be achieved as
long as the cancer cells are within the range at which the radiation
can penetrate.
For iodine-131 (131I) the beta-particle it emits carries the
majority of the radiation energy. The mean penetration of its beta
particle in soft tissues is 0.4 mm, which is equivalent to 16–160
cell diameters. By the inverse-square law, the closer the radio-
pharmaceutical molecule to the cancer cell, the greater will be the
amount of energy deposited, but it is not necessary for the radio-
pharmaceutical molecules to enter the cancer cells before cytotox-
icity can be produced. In this study, the authors wanted to
demonstrate that 131I produces its preferential cytotoxic effects
only when it is inside the malignant cell (intracellular radio-
therapy, in the words of the authors) and Lipiodol was essential for
transporting the radionuclide into the cell. They tried to show that
the Lipiodol cannot enter the cancer cells in the absence of 131I and
so produces no cytotoxic effects. The same happens for 131I alone
without Lipiodol. As stated by the authors, the iodine (127I) content
of Lipiodol is 38–40% w/v (Al-Mufti et al, 1999), whereas < 4.2
mg of sodium iodide is present in every 25 mCi of 131I solution we
used to label 1 ml of Lipiodol (Lau et al, 1999). Therefore the
percentage of 127I in Lipiodol being exchanged by 131I during the
radiolabelling is negligible. The conversion of 127I-Lipiodol to 131I-
Lipiodol should not have any change in the physiochemical prop-
erties and therefore the cells should have recognized both the
non-radioactive and the radioactive Lipiodol as identical.
Nevertheless, the authors reported very different electron microg-
raphy patterns of the two kinds of Lipiodol in both the malignant
and benign cells (Al-Mufti et al, 1999). Cold Lipiodol appeared in
the form of cytoplasmic membrane-bound vesicles, whereas 131I-
lipiodol was detected inside dead cancer cells and viable benign
cells which are claimed to be healthy by the authors.
Lipiodol (density 1.28 g ml–1) is denser than aqueous culture
medium and the two liquids are immiscible. From our experience,
even in the presence of Urografin as an emulsifying agent, the
emulsion state could not be prolonged for more than 1 h (unless it
was continuously agitated) and the Lipiodol still separated out and
settled at the bottom on standing. Hence their experimental obser-
vations might be interpreted as follows. On standing inside the
incubator for over 6 h, the 131I-Lipiodol component of the emul-
sion has separated and sunk. It came into intimate contact with the
monolayer of cells at the bottom of the well. The local radio-
activity concentrations in the vicinity of the cells were 1.0, 2.0 and
4.0 mCi of 131I in 4 ml of 131I-Lipiodol (equivalent to 250, 500 and
1000 mCi ml–1 for low, medium and high dose). Thus a high radia-
tion dose was delivered to the cells. When the cells are killed or
damaged by the radiation, the cells lost their integrity and the cell
membrane became permeable to the passage of 131I-Lipiodol
which ended up inside the cells. The endothelial cells should have
a lower population of dividing cells which are more susceptible to
radiation damage and so the effects on the benign cells were seen
to be sub-lethal while the malignant cells were killed. However,
the integrity of the endothelial cell might still have been affected in
some way and so the 131I-Lipiodol could gain its passage into some
of these benign cells.
Such radiation effects were not observed with aqueous NaI (131I)
solution. The aqueous NaI (131I) solution, being completely
miscible with the culture medium, will be distributed uniformly
throughout the 100 ml of medium and therefore the effective
radioactivity concentrations in the vicinity of the cells was really
40 mCi ml–1. So even the low dose 131I-Lipiodol was providing a
6.25 times higher local radioactivity concentration of 131I than in
the aqueous NaI (131I) solution. It is therefore logical for the
authors to observe no cytotoxic effect in the NaI (131I) solution
despite the total radioactivity in the well was four times that of the
low dose 131I-Lipiodol. We can assure the authors of a similar cell
killing effect as observed with 131I-Lipiodol if they try to increase
the NaI (131I) concentration to 250 mCi ml–1.
From our own experience in treating 26 patients with hepato-
cellular carcinoma using 131I-Lipiodol (Leung et al, 1994) and the
results of the other 12 clinical series of hepatic cancer treated with
the same agent that have recently been reviewed by us (Ho et al,
1998) we agree with the authors that the response is highly vari-
able and may partly depend on local pharmacokinetics. The other
important factor of course is the radio-sensitivity of the tumour
cells. As we have pointed out in our review article (Ho et al, 1998)
for a lesion to be completely destroyed by 131I-Lipiodol, it needs to
uptake the agent in such a way that every cancer cell lies within
2.4 mm from the radioactive oil, which is the maximum penetra-
tion of the beta-radiation from 131I. 131I-Lipiodol could hardly
concentrate in hypovascular or necrotic tumours and therefore
their responses are poor.
In conclusion, 131I-Lipiodol bound to cytoplasmic membrane of
the cancer cell as vesicles of lipids is already at a sufficiently close
distance to kill the cancer cells. It is not necessary for the 131I-
Lipiodol molecules to enter the cancer cell before it can produce
its cytotoxicity.
Letter to the Editor
In vitro assessment of Lipiodol-targeted radiotherapy for
liver and colorectal cancer cell lines
498
British Journal of Cancer (2000) 82(2), 497–498
© 2000 Cancer Research Campaign
Article no. bjoc.1999.0950Letters to the Editor 499
British Journal of Cancer (2000) 82(2), 497–498 © 2000 Cancer Research Campaign
S Ho1, WY Lau2 and WT Leung1
Departments of 1Clinical Oncology and 2Surgery, 
The Chinese University of Hong Kong,
Prince of Wales Hospital, 
Shatin, Hong Kong
REFERENCES
Al-Mufti R, Pedley RB, Marshall D, Begent RH, Hilson A, Winslet MC and Hobbs
KEF (1999) In vitro assessment of Lipiodol-targeted radiotherapy for liver and
colorectal cancer cell lines. Br J Cancer 79: 1665–1671
Ho S, Lau WY, Leung TWT and Johnson PJ (1998) Internal radiation therapy for
patients with primary or metastatic hepatic cancer. A review. Cancer 83:
1894–1907
Lau WY, Leung TWT, Ho SKW, Chan M, Machin D, Lau J, Chan ATC, Yeo W,
Mok TSK, Yu SCH, Leung N and Johnson PJ (1999) Adjuvant intra-arterial
iodine-131-labelled lipiodol for resectable hepatocellular carcinoma – a
prospective randomized trial. Lancet 353: 797–801
Leung WT, Lau WY, Ho S, Chan M, Leung N, Lin J, Ho KC, Metreweli C, Johnson
PJ and Li AKC (1994) Selective internal radiation therapy with intraarterial
131Iodine-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 35:
1313–1318